31 related articles for article (PubMed ID: 38635762)
1. Chimeric Antigen Receptor T-Cell Access in Patients with Relapsed/Refractory Large B-Cell Lymphoma: Association of Access with Social Determinants of Health and Travel Time to Treatment Centers.
Ahmed N; Sun F; Teigland C; Kilgore KM; Mohammadi I; Chambers J; Dieyi C; Feng C; Osborn J; Fu C; Gergis U
Transplant Cell Ther; 2024 Apr; ():. PubMed ID: 38697294
[TBL] [Abstract][Full Text] [Related]
2. Real-world multiple myeloma risk factors and outcomes by non-Hispanic Black/African American and non-Hispanic White race/ethnicity in the United States.
Buck T; Hartley-Brown MA; Efebera YA; Milner CP; Zonder JA; Richardson PG; Salinardi T; Rice MS
Haematologica; 2023 Nov; 109(6):1882-92. PubMed ID: 38031762
[TBL] [Abstract][Full Text] [Related]
3. Real-World Outcomes with Chimeric Antigen Receptor T Cell Therapies in Large B Cell Lymphoma: A Systematic Review and Meta-Analysis.
Jacobson CA; Munoz J; Sun F; Kanters S; Limbrick-Oldfield EH; Spooner C; Mignone K; Ayuk F; Sanderson R; Whitmore J; Wang Y; Xu H; Dickinson M
Transplant Cell Ther; 2024 Jan; 30(1):77.e1-77.e15. PubMed ID: 37890589
[TBL] [Abstract][Full Text] [Related]
4. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States.
Jacobson CA; Locke FL; Ma L; Asubonteng J; Hu ZH; Siddiqi T; Ahmed S; Ghobadi A; Miklos DB; Lin Y; Perales MA; Lunning MA; Herr MM; Hill BT; Ganguly S; Dong H; Nikiforow S; Hooper M; Kawashima J; Xu H; Pasquini MC
Transplant Cell Ther; 2022 Sep; 28(9):581.e1-581.e8. PubMed ID: 35609867
[TBL] [Abstract][Full Text] [Related]
5. Cost-Effectiveness of Chimeric Antigen Receptor T Cell Therapy in Patients with Relapsed or Refractory Large B Cell Lymphoma: No Impact of Site of Care.
Cummings Joyner AK; Snider JT; Wade SW; Wang ST; Buessing MG; Johnson S; Gergis U
Adv Ther; 2022 Aug; 39(8):3560-3577. PubMed ID: 35689726
[TBL] [Abstract][Full Text] [Related]
6. Quality-Adjusted Time without Symptoms or Toxicity: Analysis of Axicabtagene Ciloleucel versus Standard of Care in Patients with Relapsed/Refractory Large B Cell Lymphoma.
Kersten MJ; Qiao Y; Shah R; Solem C; Snider JT; To C; Cheng P; Spooner C; Perales MA
Transplant Cell Ther; 2023 May; 29(5):335.e1-335.e8. PubMed ID: 36646322
[TBL] [Abstract][Full Text] [Related]
7. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
8. Real-World and Clinical Trial Outcomes in Large B-cell Lymphoma with Axicabtagene Ciloleucel Across Race and Ethnicity.
Locke FL; Siddiqi T; Jacobson CA; Ghobadi A; Ahmed S; Miklos DB; Perales MA; Munoz J; Fingrut WB; Pennisi M; Gauthier J; Shadman M; Gowda L; Mirza AS; Abid MB; Hong S; Majhail NS; Kharfan-Dabaja MA; Khurana A; Badar T; Lin Y; Bennani NN; Herr MM; Hu ZH; Wang H; Baer A; Baro E; Miao H; Spooner C; Xu H; Pasquini MC
Blood; 2024 Apr; ():. PubMed ID: 38635762
[TBL] [Abstract][Full Text] [Related]
9. Network meta-analysis of CAR T-Cell therapy for the treatment of 3L+ R/R LBCL after using published comparative studies.
Oluwole OO; Neelapu SS; Ray MD; Limbrick-Oldfield EH; Wade SW; Kanters S; Patel AR; Locke FL
Expert Rev Anticancer Ther; 2024 Jun; 24(6):457-465. PubMed ID: 38646700
[TBL] [Abstract][Full Text] [Related]
10. Evolving Role of CAR T Cell Therapy in First- and Second-Line Treatment of Large B Cell Lymphoma.
Lionel AC; Westin J
Curr Oncol Rep; 2023 Nov; 25(11):1387-1396. PubMed ID: 37861914
[TBL] [Abstract][Full Text] [Related]
11. Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG; Xie H; Bentzen S; Kesari V; Bukhari A; El Chaer F; Lutfi F; Siglin J; Hutnick E; Gahres N; Ruehle K; Ahmad H; Shanholtz C; Kocoglu MH; Badros AZ; Yared JA; Hardy NM; Rapoport AP; Dahiya S
Neuro Oncol; 2021 Jan; 23(1):112-121. PubMed ID: 32750704
[TBL] [Abstract][Full Text] [Related]
12. Axicabtagene Ciloleucel in the Management of Follicular Lymphoma: Current Perspectives on Clinical Utility, Patient Selection and Reported Outcomes.
Mohty R; Kharfan-Dabaja MA; Chavez JC
Cancer Manag Res; 2023; 15():367-375. PubMed ID: 37155519
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]